Analysis of spatial atlas of ADC targets in immunotherapy-treated NSCLC to link compartment-specific target expression with tumor immune contexture, clinical outcome, and on-treatment remodeling.
Prof. Antoine Italiano (Gustave Roussy) delivered this oral presentation: I was honored to present our work on an integrated spatial ADC target atlas across NSCLC, bladder, gastric and endometrial cancers. Using multiplex immunofluorescence, proteomics and immune-contexture analyses, we aimed to move beyond single-marker prevalence and better understand target coverage, co-expression, spatial heterogeneity and immune geography. […]
Tumor-cell NY-ESO-1 Expression Predicts Poor Response to PD-1/PD-L1 Blockade in NSCLC
Background & rationale NY-ESO-1 is an immunogenic cancer-testis antigen and a therapeutic target for TCR-based strategies. Its value as a baseline biomarker for PD-1/PD-L1 blockade in NSCLC remains poorly defined. Because NY-ESO-1 is biologically relevant only when expressed by tumor epithelial cells, this study focused on CK7+/NY-ESO-1+ tumor cells. Study design Cohort 190 baseline FFPE […]
CCR8 positive Tregs and Their Correlation with Immunotherapy Response in Advanced Non-Small Cell Lung Cancer (NSCLC)
The chemokine receptor CCR8 is selectively expressed on activated regulatory T cells (Tregs), which are recognized as potent immunosuppressive modulators within the tumor microenvironment. Several clinical trials are currently evaluating the therapeutic benefit of selectively depleting these cells to enhance the efficacy of immune checkpoint inhibitors (ICIs). However, the prognostic and predictive value of activated […]
Why IDO1 staining can miss L-kynurenine production in colorectal and breast tumors
